Research Citations
Selected papers on buprenorphine, BPD, the endogenous opioid system, and related mechanisms.
Buprenorphine is an opioid medication. Combining it with
benzodiazepines, alcohol, or other central nervous system depressants
increases the risk of respiratory depression. See the
safety section on the main page.
← Back to main page
Borderline Personality Disorder & the Endogenous Opioid System
Proposes that core BPD behaviors — including self-injury, substance
use, frantic attachment, food restriction, and sensation seeking —
can be understood as biologically mediated attempts to
regulate a dysregulated endogenous opioid system, rather
than as purely impulsive or self-destructive acts. Chronic emptiness and
anhedonia may reflect reduced baseline opioid tone; the behaviors
themselves may function as rapid methods of endogenous opioid
activation.
Builds a detailed neurobiological model positioning
endogenous opioid, oxytocin, and vasopressin signaling as
the core substrate of BPD's interpersonal dysregulation —
connecting attachment disruption, separation distress, and social pain
sensitivity to specific neuropeptide deficits rather than to general
affective instability. Explicitly proposes that buprenorphine
warrants investigation as a treatment for BPD.
Proposes that many core features of BPD—such as distress intolerance,
interpersonal instability, self-injury, and substance use—can be understood
as attempts to temporarily correct an underlying endogenous opioid
deficit, providing short-lived relief from emotional pain and emptiness.
Measured endogenous opioid levels directly in cerebrospinal fluid of
Cluster B personality disorder patients. Those with NSSI histories had
significantly lower CSF β-endorphin and met-enkephalin
compared to matched patients without NSSI, while serotonin and dopamine
metabolites did not differ — implicating opioid deficiency specifically
in self-injurious behavior and supporting pharmacological investigation
of the opioid system.
Some of the studies below use specialized neuroimaging or genetic methods; summaries are provided for accessibility.
Using PET imaging, this study found that people with BPD show
higher baseline μ-opioid receptor availability,
interpreted by the authors as reflecting lower baseline endogenous
opioid activity, along with abnormal opioid system
responses during emotional distress. These findings provide direct
biological evidence that the brain’s internal pain- and attachment-buffering
system is dysregulated in BPD.
This study found trauma-associated epigenetic changes in OPRK1,
the gene encoding the κ-opioid receptor, in people with BPD. The findings
suggest long-term, trauma-linked alterations in the stress-related opioid
system, which is known to drive dysphoria and aversive emotional states.
Taken together, these findings support a model in which borderline
personality disorder involves both insufficient baseline μ-opioid
signaling (contributing to chronic emptiness and social pain) and
trauma-linked overactivation of the κ-opioid stress system (contributing
to dysphoria, shutdown, and self-harm urges under stress). This dual
dysregulation helps explain why treatments targeting only one pathway may
be insufficient, and why medications like buprenorphine—which partially
activate μ-opioid receptors while antagonizing κ-opioid receptors—are
mechanistically well-suited to address core features of the disorder.
Buprenorphine for Depression & Suicidality
Demonstrates that low-dose buprenorphine improves mood in people whose depression did not
respond to standard treatment options.
Randomized controlled trial in which opioid-naive patients with
severe suicidal ideation received ultra-low-dose buprenorphine
(starting 0.1–0.2 mg SL, titrated in 0.1 mg steps; mean dose 0.44
mg/day) or placebo. Buprenorphine produced rapid, significant
reduction in suicidal ideation. A post-hoc analysis found a
particularly robust treatment effect in the BPD
subgroup — the strongest available controlled clinical
signal for this application.
Summarizes emerging evidence for buprenorphine’s antidepressant and anti-suicidal effects,
including partial mu-agonism and kappa-antagonism mechanisms.
Case Reports Related to BPD
Documents an opioid-naive BPD patient initiated on
buprenorphine/naloxone (Suboxone) at 2 mg and titrated stepwise to 6 mg,
guided by crisis contact frequency as the functional endpoint. Over a
15-month comparison, crisis service contacts fell from 41 to
12, then to zero after dose optimization. Brief
discontinuation during the study period was followed by
hospitalization with symptoms consistent with pre-treatment baseline,
which resolved on resumption — strengthening the case that improvement
was attributable to the medication.
Accessing Full Text
If you have trouble accessing full-text versions of these papers:
- Search the title on PubMed or Google Scholar.
- Use Anna's Archive (or a trusted mirror) with the DOI or title.
- Try entering the DOI into a library system or institutional login.
Always use your own judgment regarding how and where you access research materials.